The Ministry of Finance proposal for the 2016 State budget brings forward part of the 150 million euro cuts in medicines reimbursements, originally sketched for the year 2017.
PIF warns against the consequences of medicines savings as they weaken the opportunities of new growth and jobs.
“The pharmaceutical industry could generate significant economic growth and create new jobs in Finland. Finnish research is not only internationally appreciated but also in active international demand provided that the country can ensure a stable and predictable operating environment. The Finnish pharmaceutical industry could contribute to improved employment and competitiveness in line with the spearhead project of Prime Minister Juha Sipilä’s Government”, General Director Jussi Merikallio of PIF points out.
PIF expects the Government to give more precise information on the measures to improve the growth potential of the health sector, in other words the pharmaceutical industry and health technology.
“Creating growth is harder than promised, if not impossible in a situation where the sector faces unreasonable cuts”, Merikallio adds.
Earlier this spring, the Government announced substantial 150 million cuts in the medicines reimbursements, on top of those already imposed in the past few years. The original plan was to implement the savings in 2017 which would have allowed for the parties involved to carefully consider the best way of making them.
PIF finds that the implementation of these consistent cuts must be agreed upon in collaboration with the actors in the pharmaceutical sector.
“The possibilities of the pharmaceutical industry to introduce new R&D projects must not be jeopardised”, Jussi Merikallio emphasises.
For further information:
Jussi Merikallio, General Manager
Pharma Industry Finland PIF
Tel: +358 50 66748